Puma Biotechnology, Inc. Posted losses of -16.01% in the Last Trade – Free Observer

Puma Biotechnology, Inc. (PBYI) belongs to the Healthcare sector with an industry focus on Biotechnology, with Mr. Alan H. Auerbach as Founder, Chairman, Chief Exec. Officer, Pres and Sec..

The company has been one of the biggest innovators in Biotechnology.

Key Statistics:

Financials:

The company reported an impressive total revenue of 0 in the last fiscal year.

If you look at the companys income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, PBYI earned gross profit of 0, in 2015 0 gross profit, while in 2016 Puma Biotechnology, Inc. (PBYI) produced 0 profit.

Currently the shares of Puma Biotechnology, Inc. (PBYI) has a trading volume of 4.25 Million shares, with an average trading volume of 1220 shares with shares dropping to a 52 week low of $19.74, and the companys shares hitting a 52 week high of $ 73.27.

Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Up in the future.

Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Puma Biotechnology, Inc. the EPS stands at -2.04 for the previous quarter, while the analysts predicted the EPS of the stock to be -1.92, suggesting the stock fell short of the analysts expectations.

Another critical number in evaluating a stock is P/E or the price to earnings ratio.

The TTM operating margin is 0%. The return on invested capital at 0%, which is good, compared to its peers.

The Free Cash Flow or FCF margin is 0%.

Stock is currently moving with a negative distance from the 200 day simple moving average of approximately -29.35%, and has a solid year to date (YTD) performance of 0% which means the stock is constantly adding to its value from the previous fiscal year end price.

Future Expectations:

The target price for Puma Biotechnology, Inc. (PBYI) is $79/share according to the consensus of analysts working on the stock, with an expected EPS of $-1.98/share for the current quarter.

See more here:
Puma Biotechnology, Inc. Posted losses of -16.01% in the Last Trade - Free Observer